logo
Bullet Train Project completion date REVEALED! Indian Railways gives massive update, work will be completed by..., it will cost...

Bullet Train Project completion date REVEALED! Indian Railways gives massive update, work will be completed by..., it will cost...

India.com6 days ago
Bullet Train: In a major development that promises to make the traveling experience of Rail passengers better and convenient. The operations of the much-awaited bullet train will commence soon in the country. According to the latest reports, the work on the Mumbai-Ahmedabad high-speed bullet train is progressing rapidly with Japan's assistance. Union Railway Minister Ashwini Vaishnaw has finally revealed the expected completion date for the project.
Railway Minister Ashwini Vaishnaw has said that the bullet train corridor between Vapi and Sabarmati will be completed by December 2027. The minister further added that the entire project from Maharashtra to the Sabarmati section is expected to be completed by December 2029. The high-speed rail project covering 508 kilometers between Ahmedabad and Mumbai is likely to be completed by December 2029.
While addressing the Parliament, Railway Minister Ashwini Vaishnaw said that the bullet train project is highly complex and technically intensive, and an exact completion timeline can only be determined once all related construction works—such as civil structures, tracks, electrical systems, signaling and telecommunication, and train set supply—are completed. Here are some of the key details: The MAHSR (Mumbai-Ahmedabad High Speed Rail) project is being built with technical and financial assistance from the Japanese government.
The project passes through the states of Gujarat, Maharashtra, and the Union Territory of Dadra and Nagar Haveli.
The project plans to build 12 stations at Mumbai, Thane, Virar, Boisar, Vapi, Bilimora, Surat, Bharuch, Vadodara, Anand, Ahmedabad, and Sabarmati. Bullet Train Costing: The Railway Minister said that as of June 30, 2025, a total of Rs 78,839 crore has been spent on the project.
The total estimated cost of the MAHSR (Mumbai-Ahmedabad High-Speed Rail) project is around Rs 1,08,000 crore
Out of Rs 1,08,000 crore, 81 percent — approximately ₹88,000 crore — is being funded by the Japan International Cooperation Agency (JICA).
The remaining 19 percent — about ₹20,000 crore — is being funded through equity contributions by the Ministry of Railways (50 percent) and the state governments of Maharashtra and Gujarat (25 percent each). Why is there a delay in the Bullet Train project?
The Union Minister,while addressing the Parliament, said that the project was impacted until 2021 due to delays in land acquisition in Maharashtra. However, at present, the entire land required for the MAHSR project (1,389.5 hectares) has been acquired. The final location survey and geotechnical investigations have also been completed, and the alignment has been finalized.
Additionally, all statutory approvals related to wildlife, Coastal Regulation Zone (CRZ), and forests have been obtained, and all civil contracts for the project have been awarded.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IndiGo profit falls sharply on geopolitical tension, Air India crash
IndiGo profit falls sharply on geopolitical tension, Air India crash

Economic Times

timea minute ago

  • Economic Times

IndiGo profit falls sharply on geopolitical tension, Air India crash

Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's largest airline IndiGo reported a sharp 20% fall in profit as air travel was impacted due to a conflict between India and Pakistan followed by weak travel sentiment after the crash of an Air India aircraft in airline, which has 60% share of India's domestic market, posted a profit of Rs 2,176.3 crore for the April–June period, down 20% from Rs 2,728.8 crore a year ago despite revenue being up by 4.73% at Rs 20,496.30 briefly restricting flights from 32 airports in airports on the north and western border in May amid border skirmishes with Pakistan following a terrorist attack in April.'The June quarter was shaped by significant external challenges that created headwinds for the entire aviation sector. Despite these industry wide disruptions, we reported a net profit margin of around 11% for the quarter ended June 2025,' Pieter Elbers, CEO of indigo a metric for profitability for airlines also dropped by 5% as the airline had to reduce fares to fill aircraft which dropped by a little over 2%.The airline though gave optimistic note and outlined plans for expansion. Elbers said the airline has begun long-haul services to Europe, launching flights to Amsterdam and Manchester in early July. Given strong demand, IndiGo will double its frequency to Amsterdam and add a fourth weekly flight to Manchester. A reciprocal codeshare with KLM will also expand the airline's reach across Europe.'We remain firm on our full year capacity guidance of early double digit capacity addition. While we have taken a number of proactive steps as part of our plan to align capacity with the demand, we are using the downtime to conduct structural inspections on some aircrafts and implementing fleet upgrades, ensuring the fleet is fully prepared for the seasonally strong third quarter,' Chief Financial Officer Gaurav Negi said in a post-results call with debuting on the Delhi–Mumbai route late last year, IndiGo's business class product (called Stretch) has now been extended to flights to Bangkok and will soon launch on routes to Singapore and Dubai. Elbers said the market response has been encouraging, with load factors improving the domestic front, IndiGo recently began operations from Hindon airport in Delhi and is looking to expand its network further.

Hyundai Motor India Q1 net slides 8% to ₹1,369 crore
Hyundai Motor India Q1 net slides 8% to ₹1,369 crore

The Hindu

time4 minutes ago

  • The Hindu

Hyundai Motor India Q1 net slides 8% to ₹1,369 crore

Hyundai Motor India Ltd. (HMIL) for the first quarter ended June 30, 2025 reported 8% fall in consolidated net profit at 1,369 crore. The company's revenue during the quarter also dropped 5.36% to Rs.16,413 crore from Rs.17,344 crore a year ago. The company witnessed accelerated exports growth and volumes increased 13% on YoY basis, while domestic growth remained subdued, amid macro challenges, the company said in a filing. Unsoo Kim, Managing Director, HMIL said, 'We continued our stated strategy of 'Quality of Growth' in the first quarter of FY26 with balance between domestic & exports, market share and profitability.' 'This strategy helped us to sustain strong EBITDA margin of 13.3% during the quarter, despite tough macro-economic environment,' he said. 'Moving forward, we anticipate gradual recovery in domestic demand sentiments, driven by onset of monsoon & festive season coupled with government policy measures, while on the exports front, we are confident to maintain a positive momentum, in line with our growth commitments,' he added.

JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains
JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains

Business Standard

time4 minutes ago

  • Business Standard

JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains

JB Chemicals and Pharmaceuticals posted a 14.4 per cent increase in its consolidated net profit at Rs 202 crore for the first quarter of the financial year (Q1FY26). Revenue from operations also rose by 8.9 per cent to Rs 1,093 crore. Sequentially, net profit increased by 38 per cent, with revenue also growing by 15 per cent. Nikhil Chopra, chief executive officer and wholetime director, JB Pharma, stated: 'The domestic business recorded approximately 14 per cent value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands and their franchises are also performing well. The CDMO business momentum is likely to sustain in the coming quarters.' Going forward, the company will focus on increasing topline growth along with optimisation of costs and organisational efficiencies. It expects the domestic and CDMO segments to lead growth and profitability. The company claims it is one of the fastest-growing domestic pharmaceutical companies among the top 25 organisations, as per IQVIA MAT June 2025 data. JB Pharma's ophthalmology portfolio delivered robust 19 per cent growth, reaching Rs 57 crore in Q1FY26. The Razel franchise crossed Rs 100 crore in MAT June 2025, up from Rs 69 crore in MAT June 2023, while Azmarda sales rose to Rs 75 crore from Rs 69 crore in MAT June 2024. International business revenue grew 2 per cent year-on-year (Y-o-Y) to Rs 416 crore, compared to Rs 409 crore. However, the international formulations segment declined 2 per cent to Rs 283 crore. While branded generics exports grew during the quarter, markets such as Russia, the US and South Africa remained flat or marginally declined. The CDMO business posted an 8 per cent increase to Rs 115 crore, with strong momentum expected to continue. The active pharmaceutical ingredient (API) segment reported 38 per cent Y-o-Y growth, rising to Rs 18 crore from Rs 13 crore. The results were announced after market hours. JB's share fell by 1.08 per cent, ending the day's trade at Rs 1,782.90 apiece on the BSE.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store